Cardiometabolic Drugs Market Size & Share, by Drug Type (Weight Loss, Antidiabetics, Anticoagulants, Antiplatelet, Impaired Glucose Tolerance, Insulin Resistance, Hypertension, Dyslipidemia); Disease Type (Congestive Heart Failure, Hypertension, Diabetes, Obesity); Distribution Channel (Hospitals, Clinics, Retail Pharmacies, Online) - Global Supply & Demand Analysis, Growth Forecasts, Statistics Report 2023-2035

  • Report ID: 4146
  • Published Date: Feb 24, 2023
  • Report Format: PDF, PPT

Companies Dominating the Cardiometabolic Drugs Landscape

    • GSK plc
      • Company Overview
      • Business Strategy
      • Key Product Offerings
      • Financial Performance
      • Key Performance Indicators
      • Risk Analysis
      • Recent Development
      • Regional Presence
      • SWOT Analysis
    • Lupin Limited
    • Merck KGaA
    • Romark L.C.
    • Pfizer Inc.
    • Endo International plc
    • Bayer AG
    • Jazz Pharmaceuticals plc
    • Canopy Growth Corporation
    • InMed Pharmaceuticals Inc.

Browse Key Market Insights with Data Illustration:


In The News

  • GSK plc acquires the approval from US Food and Drug Administration (FDA) for its Priorix, a vaccine for mumps, measles, and rubella in children 12 months old or above it.

  •  Lupin Limited to merge its path with Yabao Pharmaceutical Co., inc., based in China, to fulfill the escalating demand in the Chinese market for quality drugs with the pediatric formulation.

Author Credits:  Radhika Gupta, Shivam Bhutani

  • Report ID: 4146
  • Published Date: Feb 24, 2023
  • Report Format: PDF, PPT

Frequently Asked Questions (FAQ)

Increasing awareness toward the development of novel drugs and the growing demand for drugs to cure cardiometabolic diseases are the major factors driving the growth of the cardiometabolic drugs market.

The market is anticipated to attain a CAGR of ~6% over the forecast period, i.e., 2023 – 2035.

The possibility of significant side effects is estimated to hamper the market growth.

The market in the North America region is projected to hold the largest market share by the end of 2035 and provide more business opportunities in the future.

The major players in the market are GSK plc, Lupin Limited, Merck KGaA, Romark L.C., Pfizer Inc., Endo International plc, Bayer AG, Jazz Pharmaceuticals plc, Canopy Growth Corporation, InMed Pharmaceuticals Inc., and other key players.

The company profiles are selected based on the revenues generated from the product segment, the geographical presence of the company which determines the revenue-generating capacity as well as the new products being launched into the market by the company.

The market is segmented by drug type, disease, distribution channel, and by region.

The hospital segment is anticipated to garner the largest market size by the end of 2035 and display significant growth opportunities.
Inquiry Before Buying Request Free Sample

FREE Sample Copy includes market overview, growth trends, statistical charts & tables, forecast estimates, and much more.

 Request Free Sample Copy

Have questions before ordering this report?

Inquiry Before Buying